EP3842554 - BIOMARKERS FOR RESPONSE TO PI3K INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 20.10.2023 Database last updated on 24.08.2024 | |
Former | The patent has been granted Status updated on 11.11.2022 | ||
Former | Grant of patent is intended Status updated on 23.06.2022 | ||
Former | Request for examination was made Status updated on 07.01.2022 | ||
Former | The application has been published Status updated on 28.05.2021 | Most recent event Tooltip | 24.05.2024 | Lapse of the patent in a contracting state New state(s): BE, FR, GB, IT | published on 26.06.2024 [2024/26] | Applicant(s) | For all designated states Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 / US | [2021/26] | Inventor(s) | 01 /
MOYNAHAN, Mary, Ellen 300 E 66TH ST New York, NY 10065-6800 / US | 02 /
GASKELL, Alice 39-10 51st St.Woodside, NY 11377 / US | [2021/26] | Representative(s) | Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB | [2021/26] | Application number, filing date | 20201617.6 | 08.05.2015 | [2021/26] | Priority number, date | US201461991165P | 09.05.2014 Original published format: US 201461991165 P | US201461992173P | 12.05.2014 Original published format: US 201461992173 P | US201462004518P | 29.05.2014 Original published format: US 201462004518 P | [2021/26] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3842554 | Date: | 30.06.2021 | Language: | EN | [2021/26] | Type: | B1 Patent specification | No.: | EP3842554 | Date: | 14.12.2022 | Language: | EN | [2022/50] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 06.05.2021 | Classification | IPC: | C12Q1/6886 | [2021/26] | CPC: |
C12Q1/6886 (EP,US);
A61K31/4196 (US);
A61K31/566 (US);
C12Q1/68 (US);
C12Q2600/106 (EP);
C12Q2600/118 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/06] |
Former [2021/26] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | BIOMARKER FÜR REAKTION AUF PI3K-HEMMER | [2021/26] | English: | BIOMARKERS FOR RESPONSE TO PI3K INHIBITORS | [2021/26] | French: | BIOMARQUEURS UTILISABLES POUR ÉVALUER LA RÉPONSE AUX INHIBITEURS DE LA PI3K | [2021/26] | Examination procedure | 30.12.2021 | Amendment by applicant (claims and/or description) | 30.12.2021 | Examination requested [2022/06] | 30.12.2021 | Date on which the examining division has become responsible | 24.06.2022 | Communication of intention to grant the patent | 04.11.2022 | Fee for grant paid | 04.11.2022 | Fee for publishing/printing paid | 04.11.2022 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP15789311.6 / EP3140427 | Opposition(s) | 15.09.2023 | No opposition filed within time limit [2023/47] | Fees paid | Renewal fee | 12.02.2021 | Renewal fee patent year 03 | 12.02.2021 | Renewal fee patent year 04 | 12.02.2021 | Renewal fee patent year 05 | 12.02.2021 | Renewal fee patent year 06 | 13.05.2021 | Renewal fee patent year 07 | 18.03.2022 | Renewal fee patent year 08 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 14.12.2022 | AT | 14.12.2022 | CZ | 14.12.2022 | DK | 14.12.2022 | EE | 14.12.2022 | ES | 14.12.2022 | FI | 14.12.2022 | HR | 14.12.2022 | IT | 14.12.2022 | LT | 14.12.2022 | LV | 14.12.2022 | MC | 14.12.2022 | NL | 14.12.2022 | PL | 14.12.2022 | RO | 14.12.2022 | RS | 14.12.2022 | SE | 14.12.2022 | SI | 14.12.2022 | SK | 14.12.2022 | SM | 14.12.2022 | NO | 14.03.2023 | GR | 15.03.2023 | IS | 14.04.2023 | PT | 14.04.2023 | GB | 08.05.2023 | IE | 08.05.2023 | LU | 08.05.2023 | BE | 31.05.2023 | CH | 31.05.2023 | FR | 31.05.2023 | LI | 31.05.2023 | [2024/26] |
Former [2024/21] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
DK | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
MC | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SI | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
IE | 08.05.2023 | ||
LU | 08.05.2023 | ||
CH | 31.05.2023 | ||
LI | 31.05.2023 | ||
Former [2024/09] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
DK | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
MC | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SI | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
LU | 08.05.2023 | ||
CH | 31.05.2023 | ||
LI | 31.05.2023 | ||
Former [2024/08] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
DK | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
MC | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SI | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
LU | 08.05.2023 | ||
Former [2023/51] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
DK | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SI | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
Former [2023/46] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
DK | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
Former [2023/39] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
IS | 14.04.2023 | ||
PT | 14.04.2023 | ||
Former [2023/38] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
PL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SK | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
PT | 14.04.2023 | ||
Former [2023/37] | AL | 14.12.2022 | |
AT | 14.12.2022 | ||
CZ | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
PT | 14.04.2023 | ||
Former [2023/35] | AT | 14.12.2022 | |
CZ | 14.12.2022 | ||
EE | 14.12.2022 | ||
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
RO | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
PT | 14.04.2023 | ||
Former [2023/34] | EE | 14.12.2022 | |
ES | 14.12.2022 | ||
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
PT | 14.04.2023 | ||
Former [2023/33] | ES | 14.12.2022 | |
FI | 14.12.2022 | ||
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
SM | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
Former [2023/29] | FI | 14.12.2022 | |
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
NL | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
Former [2023/25] | FI | 14.12.2022 | |
HR | 14.12.2022 | ||
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
RS | 14.12.2022 | ||
SE | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
Former [2023/23] | FI | 14.12.2022 | |
LT | 14.12.2022 | ||
LV | 14.12.2022 | ||
SE | 14.12.2022 | ||
NO | 14.03.2023 | ||
GR | 15.03.2023 | ||
Former [2023/22] | FI | 14.12.2022 | |
LT | 14.12.2022 | ||
SE | 14.12.2022 | ||
NO | 14.03.2023 | ||
Former [2023/20] | LT | 14.12.2022 | |
NO | 14.03.2023 | Documents cited: | Search | [Y]WO2013015833 (GENENTECH INC [US], et al) [Y] 1-15 * the whole document * * Fig. 5; p. 7, ll. 4-8; p. 20, ll. 9-23; p. 33, l. 28 - p. 35, l. 24 *; | [Y]WO2013144249 (NOVARTIS AG [CH], et al) [Y] 1-15 * the whole document * * p. 3, first par. *; | [XY]US2014044706 (BELVIN MARCIA [US], et al) [X] 1,2,5-13,15 * the whole document * * par. 9, 13, 20, 35-39, 47, 48, 125, 171-177, claims 1, 28, 44, 49, 51, 59, Fig. 1-4 * [Y] 3,4,14; | [X] - Mary Ellen Moynahan, "Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3Kalpha inhibitor plus letrozole (L) or exemestane (E)", Journal of Clinical Oncology, vol. 32, no. 15, doi:10.1200/jco.2014.32.15_suppl.517, (20140501), URL: http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.517, (20171013), XP002774657 [X] 1-15 * the whole document * DOI: http://dx.doi.org/10.1200/jco.2014.32.15_suppl.517 | [Y] - JEFFREY A ENGELMAN ET AL, "Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers", NATURE MEDICINE, (20081201), vol. 14, no. 12, doi:10.1038/nm.1890, ISSN 1078-8956, pages 1351 - 1356, XP055012919 [Y] 1-15 * the whole document * * abstract, Fig. 2 * DOI: http://dx.doi.org/10.1038/nm.1890 | [Y] - ISAKOFF STEVEN J ET AL, "Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20051201), vol. 65, no. 23, doi:10.1158/0008-5472.CAN-05-2612, ISSN 0008-5472, pages 10992 - 11000, XP002534440 [Y] 1-15 * the whole document * * abstract, p. 10995, Fig. 2B * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-05-2612 | [Y] - ELKABETS M ET AL, "MTORC1 inhibition is required for sensitivity to PI3K p110[alpha] inhibitors in PIK3CA-mutant breast cancer", SCIENCE TRANSLATIONAL MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE (A A A S), US, (20130731), vol. 5, no. 196, doi:10.1126/SCITRANSLMED.3005747, ISSN 1946-6234, pages 1 - 15, XP008169805 [Y] 1-15 * the whole document * * Fig. 1 * DOI: http://dx.doi.org/10.1126/scitranslmed.3005747 | [Y] - SAUVEUR-MICHEL MAIRA ET AL, "PI3K inhibitors for cancer treatment: where do we stand?", BIOCHEMICAL SOCIETY TRANSACTIONS, (20090201), vol. 37, no. 1, doi:10.1042/BST0370265, ISSN 0300-5127, page 265, XP055077107 [Y] 1-15 * the whole document * * Table 1 * DOI: http://dx.doi.org/10.1042/BST0370265 | by applicant | WO2012052745 | WO2013049581 | - "NCBI", Database accession no. GI: 126302584 | - SAMUELS et al., Science, (20040000), vol. 304, no. 5670, page 554 | - CAMPBELL et al., Cancer Res., (20040000), vol. 64, no. 21, pages 7678 - 7681 | - LEE et al., Oncogene, (20050000), vol. 24, pages 1477 - 1480 | - CIZKOVA et al., Breast Cancer Res., (20120000), vol. 14, no. 1, page R28 | - BACHMAN et al., Cancer Biol. Ther., (20040000), vol. 3, no. 8, pages 772 - 775 | - KARAKAS et al., British Journal of Cancer, (20060000), vol. 94, pages 455 - 459 | - SCHMIDT-KITTLER et al., Oncotarget, (20100000), vol. 1, no. 5, pages 339 - 348 | - WU et al., Med. Chem. Comm., (20120000), vol. 3, pages 659 - 662 | - HAYAKAWA et al., Bioorg. Med. Chem., (20070000), vol. 15, no. 17, pages 5837 - 5844 | - P. SUNNUCKS et al., Genetics, (19960000), vol. 144, pages 747 - 756 | - S. M. ALJANABII. MARTINEZ, Nucl. Acids Res., (19970000), vol. 25, pages 4692 - 4693 | - S. GUSTINCICH et al., BioTechniques, (19910000), vol. 11, pages 298 - 302 | - J. B. W. HAMMOND et al., Biochemistry, (19960000), vol. 240, pages 298 - 300 | - FORSHEW et al., Sci. Transl. Med., (20120000), vol. 4, no. 136, page 136 |